HIV Seropositivity Clinical Trial
Official title:
Comparative Study of Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV + Men Being Given Tenofovir With FTC, Emtricitabine (TRUVADA®), or Without (VIREAD®), as Part of Their Antiretroviral Therapy.
HIV+ patients are considered at risk for excessive bone fragility. Several factors could
contribute: age, male sex, low body mass index (BMI), HIV infection per se, vitamin D
deficiency, using tenofovir/a protease inhibitor (time on and/or current use). Tenofovir is
used in a backbone of nucleosides/nucleotides analogues with emtricitabine (FTC), licensed
as TRUVADA®, or without this analogue, licensed as VIREAD®. FTC closely resembles lamivudine
(3TC) but is 5-fluorinated, the daily intake of fluoride is ~15 mg. Fluoride induces bone
formation by stimulating osteoblasts, of often impaired bone quality.
The aim of the study is to compare in a cross-sectional design fluoride levels, bone
renewal, bone mineral density (BMD) in HIV+ male patients treated by TRUVADA® or VIREAD® for
more than 60 months. The patients will be randomly selected, then matched according to age,
ethnic origin, BMI.
Fluoride metabolism will be studied by measurement of fluoride in blood and in daily urine, bone remodelling by measurement of P1NP. Dual X-ray absorptiometry (DXA) will be used to determine the areal bone mineral density (aBMD) of the lumbar spine, femoral neck and distal radius. Volumetric BMD (v-BMD) and micro-architecture of distal radius and tibia will be studied using a HR-pQCT scan (Xtreme, Scanco). ;
Observational Model: Cohort, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03661203 -
Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
|
||
Completed |
NCT00381212 -
A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05983536 -
The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
|
||
Recruiting |
NCT04832477 -
Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US
|
N/A | |
Active, not recruiting |
NCT04044586 -
HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
|
||
Completed |
NCT03218839 -
Evaluation of the PrePex Device for Rapid Scale-up of VMMC, Phase 3 Field Implementation Trial With HIV + Adult Males
|
N/A | |
Active, not recruiting |
NCT00797030 -
Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus
|
Phase 4 | |
Recruiting |
NCT04088916 -
Proviral DNA as a Target for HIV-1 Resistance Analysis
|
||
Completed |
NCT03367130 -
Improving Clinic Attendance for Medication Collection Among HIV Positive Individuals in Nepal
|
N/A | |
Completed |
NCT04849767 -
National Survey About Trajectory and Life Conditions of HIV Trans People in France
|
||
Completed |
NCT05674682 -
Seroincidence Study Among Men Who Have Sex With Men and Transgender Women - The ImPrEP Seroincidence Study
|
N/A | |
Recruiting |
NCT05174234 -
Precariousness and Sexual Vulnerability of People From Haiti Living With or Without HIV in French Guiana
|
||
Completed |
NCT00130819 -
Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants
|
Phase 2 | |
Active, not recruiting |
NCT04706624 -
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
|
N/A | |
Recruiting |
NCT03858478 -
Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST
|
Phase 4 | |
Completed |
NCT02154971 -
Assessment of Age-related Hearing Loss in HIV-1 Patients
|
||
Recruiting |
NCT03311945 -
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
|
Phase 3 | |
Recruiting |
NCT03333083 -
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
|
Phase 3 | |
Recruiting |
NCT03795415 -
ANRS12373 GUNDO SO - Evaluation of an Empowerment Program for WLHIV in Mali
|
||
Completed |
NCT01881971 -
Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center
|
Early Phase 1 |